CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and
efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of
refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after
previous CAR-T cell therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University